Cannabinoid Hyperemesis Syndrome: Why Standard Anti-Nausea Drugs Fail and What Works Instead

Standard antiemetics commonly fail in cannabinoid hyperemesis syndrome, but benzodiazepines, antipsychotics, and topical capsaicin show promise based on the condition's unique pathophysiology.

Richards, John R·The Journal of emergency medicine·2018·Moderate EvidenceReview
RTHC-01812ReviewModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

CHS may result from the endocannabinoid system being overwhelmed by chronic cannabis use, with acute episodes triggered by stress or fasting. Standard antiemetics often fail because CHS involves different pathways than typical nausea. Benzodiazepines and antipsychotics work through their sedating effects, while capsaicin activates TRPV1 receptors through an entirely different mechanism.

Key Numbers

CHS has become more prevalent with increasing cannabis potency and legalization. Treatment failure with standard antiemetics is common. Capsaicin, benzodiazepines, and antipsychotics represent the three main alternative treatment approaches.

How They Did This

Review of CHS pathophysiology and published literature on pharmacologic treatment in the emergency department setting.

Why This Research Matters

CHS is increasingly common as cannabis potency and use rise, and patients often make repeated ER visits because standard treatments do not work. Understanding why and which alternatives are effective can reduce suffering and healthcare costs.

The Bigger Picture

CHS illustrates the principle that the endocannabinoid system has limits. Chronic overstimulation can fundamentally disrupt the body's stress response and homeostatic mechanisms. As cannabis potency continues to increase, CHS may become even more common.

What This Study Doesn't Tell Us

Limited high-quality research despite increasing CHS prevalence. Most treatment evidence comes from case reports and case series rather than controlled trials. The exact mechanism of CHS remains incompletely understood.

Questions This Raises

  • ?What level of cannabis use triggers CHS?
  • ?Why do some heavy users develop it while others do not?
  • ?Could genetic factors determine susceptibility?
  • ?Is there a role for preventive treatment in high-risk users?

Trust & Context

Key Stat:
Standard antiemetics commonly fail in CHS; benzodiazepines, antipsychotics, and capsaicin work through different mechanisms.
Evidence Grade:
Moderate - well-reasoned mechanistic review, but treatment evidence is largely from case reports rather than controlled trials.
Study Age:
Published in 2018. CHS treatment research has expanded since.
Original Title:
Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.
Published In:
The Journal of emergency medicine, 54(3), 354-363 (2018)
Authors:
Richards, John R(7)
Database ID:
RTHC-01812

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why don't regular anti-nausea drugs work for CHS?

CHS involves disruption of the endocannabinoid system's regulation of stress and homeostasis, which is different from the pathways targeted by standard antiemetics. That's why alternative approaches like benzodiazepines and capsaicin are more effective.

What causes cannabinoid hyperemesis syndrome?

The review suggests CHS occurs when chronic cannabis use overwhelms the endocannabinoid system, which normally regulates stress response. Acute episodes may be triggered by stress or fasting in chronic users with already-disrupted hormonal feedback systems.

Read More on RethinkTHC

Cite This Study

RTHC-01812·https://rethinkthc.com/research/RTHC-01812

APA

Richards, John R. (2018). Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.. The Journal of emergency medicine, 54(3), 354-363. https://doi.org/10.1016/j.jemermed.2017.12.010

MLA

Richards, John R. "Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.." The Journal of emergency medicine, 2018. https://doi.org/10.1016/j.jemermed.2017.12.010

RethinkTHC

RethinkTHC Research Database. "Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatm..." RTHC-01812. Retrieved from https://rethinkthc.com/research/richards-2018-cannabinoid-hyperemesis-syndrome-pathophysiology

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.